Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037591 | 1.00 | NR4A2 (0.44) | NR4A2ESRRGMEN1RAB9AKMT2A | |
| SCHEMBL7369135 | 0.84 | MEN1 (0.38) | NR4A2ESRRGMEN1RAB9AKMT2A | |
| SCHEMBL7369137 | 0.84 | MEN1 (0.38) | NR4A2ESRRGMEN1RAB9AKMT2A | |
| SCHEMBL7369868 | 0.84 | NR4A2 (0.47) | NR4A2MEN1KMT2AMMP1MMP3 | |
| SCHEMBL7374458 | 0.84 | NR4A2 (0.47) | NR4A2MEN1KMT2AMMP1MMP3 | |
| SCHEMBL3039559 | 0.83 | NR4A2 (0.55) | NR4A2MEN1RAB9AKMT2AMMP1 | |
| SCHEMBL7372235 | 0.83 | NR4A2 (0.55) | NR4A2MEN1RAB9AKMT2AMMP1 | |
| SCHEMBL7364436 | 0.82 | HDAC1 (0.47) | NR4A2MEN1RAB9AKMT2ATSHR | |
| SCHEMBL7367268 | 0.82 | TDP1 (0.47) | NR4A2MEN1KMT2A | |
| SCHEMBL7369241 | 0.82 | PYCR1 (0.49) | NR4A2MEN1KMT2AEPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | claimed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | claimed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | claimed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | claimed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| WO-1998054123-A1 | SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1998-12-03 | — | — | WO | claimed |
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| US-6100260-A | ((3-(1-(2-FLUORO-BIPHENYL-4-YL)-ETHYL)-ISOXAZOL-5-YLIMINO) -MORPHOLIN-4-YL-M ETHYL)-AMINE, FOR EXAMPLE; ADMINISTERING TO TREAT AUTOIMMUNE DISEASES AND INFLAMMATION | SUMITOMO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-08 | — | — | US | disclosed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998054123-A1 | SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | NR4A2 2485/4885ESRRG 3440/4885MEN1 829/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | NR4A2 2485/4885ESRRG 3440/4885MEN1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.